3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
21
Lung Neoplasms
12
Squamous Cell Carcinoma of Head and Neck
8
Prostatic Neoplasms
8
Stomach Neoplasms
4
Prostatic Neoplasms, Castration-Resistant
4
Breast Neoplasms
4
Neoplasms
3
Neoplasm Metastasis
3
Endometrial Neoplasms
3
Carcinoma, Transitional Cell
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Melanoma
2
Lymphoid Interstitial Pneumonia
2
Head and Neck Neoplasms
2
Esophageal Neoplasms
2
Carcinoma
2
Anatomic Stage I Breast Cancer AJCC v8
2
Vaccinia
1
Uterine Cervical Neoplasms
1
Tongue Neoplasms
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Non-small Cell Lung Cancer Metastatic
1
Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
1
Interventions
durvalumab
2
ruxolitinib
1
repotrectinib
1
cemiplimab
1
atezolizumab
1
Pemetrexed
1
Nivolumab
1
Immunotherapy
1
Docetaxel
1
Cisplatin
1
CPI-0610
1
Biopsy
1
Bevacizumab
1
ALT-803
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
Docetaxel
×
30 days
×
Clear all
NCT06463665
2026-06-04
VIRO-25
Genelux Corporation
Phase 2
Recruiting
142 enrolled